Hikal Limited Q4 FY26 Results: Revenue ₹519 Cr, EBITDA Margin 20.3%
Hikal Limited reported Q4 FY26 revenue of ₹519 crore and EBITDA margin of 20.3%. Full-year FY26 revenue was ₹1,713 crore with a 12.9% EBITDA margin. The company sees improvement in Pharma and Crop Protection segments and expects new contributions from Specialty Chemicals and Personal Care from FY27. A total dividend of 30% was declared.
The results show a positive recovery and improved margins, which is significant for the company's financial health and future growth prospects. However, the overall financial year performance still shows a decline in PAT, moderating the immediate impact.
The company reported improved operating performance with higher revenue and EBITDA margin in Q4 FY26 compared to previous periods, indicating a positive trend and recovery.
Hikal Limited announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company reported a revenue of ₹519 crore and an EBITDA margin of 20.3% for Q4 FY26, marking an improvement in operating performance and a step-up from previous periods.
For the full year FY26, the company's revenue stood at ₹1,713 crore with an EBITDA margin of 12.9%. The Pharmaceutical business showed steady improvement, driven by demand in Own Products and CDMO segments, supported by strategic investments in a high-potency laboratory and a pilot plant. The Crop Protection business recovered with increased volumes and improving customer demand, although pricing remains a concern. The Animal Health segment also saw steady strengthening.
Hikal's priorities include improving product mix, expanding the CDMO pipeline, and diversifying into higher-value Specialty Chemicals and Personal Care segments, with commercialization expected from FY27 onwards. The company highlighted its Business Excellence framework, focusing on procurement, integration, yield improvements, and solvent recovery.
In Q4 FY26, Profit After Tax (PAT) was ₹14 crore. The total dividend for the year is 30%, including a final dividend of 20%. The company maintained balance sheet discipline and focused on improving operating cash flow and Return on Capital Employed.
What to do with a filing like this
Hikal Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Hikal Limited. Read the original for the full detail.